Cedirogant - AbbVie
Alternative Names: ABB-157; ABBV 157; ABV-157Latest Information Update: 20 Jan 2025
At a glance
- Originator Inventiva Pharma
- Developer AbbVie
- Class Acetic acids; Antipsoriatics; Chlorobenzenes; Fluorinated hydrocarbons; Indoles; Piperidines; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver disorders; Plaque psoriasis
Most Recent Events
- 09 Sep 2024 Pharmacokinetics data from the phase Ib trial in Liver disorders presented at the 2024 American College of Clinical Pharmacology Annual Meeting (ACCP-2024)
- 24 Mar 2024 Pharmacokinetics data from a phase I drug-drug interaction trial presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2024)
- 24 Mar 2024 Abbvie initiates a phase I drug-drug interaction trial for Cedirogant prior to March 2024